Byrock Technologies Limited
An equine pharmaceutical company dedicated to improving the health of horses worldwide — advancing PTP-102, an investigational therapeutic targeting the underlying cause of laminitis.
Mission
At Byrock Technologies our mission is to support veterinarians, owners and the equine industry in their task to improve the health of horses worldwide.
Quality
We uphold stringent standards in pharmaceutical development, advancing PTP-102 through proof-of-concept studies with a focus on safety and scientific rigour.
Teamwork
Our multidisciplinary team combines veterinary, scientific, regulatory, legal and commercial expertise to address equine health challenges end to end.
Innovation
We target critical gaps in equine healthcare, pioneering treatments that merge scientific advancement with real market need. PTP-102 is our first step.
Our team
A collaboration of consultants and professionals spanning veterinary medicine, research, law and business.